Novartis collaborates with Xencor over bispecific antibodies for cancer
Swiss pharma giant Novartis (NOVN: VX) has added bispecific antibodies to its growing immuno-oncology portfolio through a collaboration and licensing deal with US biotech firm Xencor (Nasdaq: XNCR).
The collaboration, which will see Novartis pay its new partner a $150 million upfront payment, will include the co-development of Xencor's two T-cell engaging bispecific antibodies targeting acute myeloid leukemia and B-cell malignancies.
Novartis receives rights to develop four additional programs and the right to use Xencor's antibody engineering platform to develop up to 10 additional antibodies in immuno-oncology and for other diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze